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Abstract
The inﬂuence of radiotherapy duration on the outcomes of limited-disease small-cell lung cancer has been
controversial. In this study, all 81 patients completed 45 Gy in 30 fractions and concurrent chemotherapy of
platinum and etoposide. The median radiotherapy duration was 25 days. The median survival time was 30
months, and the radiotherapy duration was identiﬁed as one of the signiﬁcant survival predictors (hazard ratio,
1.08; 95% conﬁdence interval, 1.01-1.15). The main reason for prolonging the radiotherapy duration was febrile
neutropenia, not esophagitis.
Background: The hypothesis of this retrospective study was that the duration of twice-daily (BID) thoracic radio-
therapy (TRT) and time from the start of any treatment to the end of chest irradiation (SER) would predict outcomes in
limited-disease small-cell lung cancer.Materials and Methods: All 81 patients received 45 Gy in 30 fractions BID with
a  6-hour interval and concurrent chemotherapy of platinum and etoposide. Results: The median radiotherapy
duration was 25 days (range, 21-38 days). The 5-year overall survival rates were 26.2% (95% conﬁdence interval [CI],
14.3%-38.0%), and the median survival time was 30 months (95% CI, 15.5-44.5 months). Using multivariate
regression analysis, the signiﬁcant predictors of survival were the sum of the diameters of the primary tumor and
metastatic lymph nodes, male gender, age  60 years, and the duration of BID-TRT (hazard ratio [HR], 1.15; 95% CI,
1.06-1.25; HR, 2.38; 95% CI, 1.13-5.02; HR, 2.38; 95% CI, 1.10-5.17; and HR, 1.08; 95% CI, 1.01-1.15, respectively).
A total of 70 of 81 patients (86%) received radiotherapy during the ﬁrst chemotherapy cycle. The median SER was 29
days (range, 21-109 days). The 5-year local control rate was 48.7% (95% CI, 33.9%-63.6%). The signiﬁcant predictors
of local control were the sum of the diameters of the primary tumor and metastatic lymph nodes, age  60 years, and
SER (HR, 1.18; 95% CI, 1.06-1.31; HR, 4.18; 95% CI, 1.23-14.24; and HR, 1.02; 95% CI, 1-1.04, respectively).
Conclusions: The duration of BID-TRT and SER were identiﬁed as one of the signiﬁcant predictors of survival and
local control in limited-disease small-cell lung cancer treated with concurrent chemoradiotherapy at 45 Gy in 30
fractions, respectively.
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BID-TRT Duration as Survival Predictor in LD-SCLCIntroduction Table 1 Patient Characteristics and Treatment FactorsPatient Characteristic N (%)
Number of patients 81
Age, years
Median 66
Range 40-86
Gender
Male 60 (74)
Female 21 (26)
Performance status
0 37 (46)
1 41 (51)
2 2 (2)
3 0
4 1 (1)a
Stage
IA 1 (1)
IB 2 (2)
IIA 11 (14)
IIB 7 (9)
IIIA 34 (42)
IIIB 26 (32)
Sum of the diameters of the primary tumor
and metastatic lymph nodes, cm
Median 7.8
Range 1.4-17.2
Number of patients with a history of smoking 78 (96)
Number of patients with performing positron
emission tomography for staging
52 (64)
Number of patients with diabetes mellitus 17 (21)
Number of patients complicated with interstitial
pneumonia before chemoradiotherapy
6 (7)
Pretreatment hemoglobin level, g/dL
Median 13.6
Range 8.7-17.9
Pretreatment pro-gastrin-releasing peptide
level, pg/mL
Median 205
Range 16-5177
Number of patients with performing 3-
dimensional computed tomography simulation
61 (75)
Irradiated volume of the body, cm3
Median 2580
Range 722-5280
Initial chemotherapy regimen
Cisplatin and etoposide 66 (81)
Carboplatin and etoposide 15 (19)
Number of cycles of performing chemotherapy
1 1 (1)
2 6 (7)
3 4 (5)
4 70 (86)The standard treatment for limited-disease small-cell lung cancer
(LD-SCLC) is chemoradiotherapy,1 and the standard radiotherapy
regimen used is twice-daily (BID) thoracic radiotherapy (TRT). It is
generally delivered at a total dose of 45 Gy in 30 fractions over 3
weeks to decrease the duration of radiotherapy relative to conven-
tionally fractionated radiotherapy.2 However, a pattern of care study
revealed that BID-TRT was performed on 21.5% of patients with
small-cell lung cancer,3 and the suggested reasons for this were as
follows: it was challenging to perform BID radiotherapy in clinical
practice; there was frequent chemoradiotherapy-induced severe
esophagitis in the BID-TRT group; or there was an alternative
choice involving once-daily high-dose radiotherapy.4 Thus, few
studies have investigated the predictors of outcomes in LD-SCLC
patients treated with BID-TRT.5 The duration of BID-TRT in
LD-SCLC has not yet been established as a predictor of outcomes.
Therefore, we retrospectively investigated the predictors of out-
comes in LD-SCLC including the duration of BID-TRT thoracic
radiotherapy. In addition, we included time from the start of any
treatment to the end of chest irradiation (SER)6 in these analyses.
Materials and Methods
A total of 105 patients with LD-SCLC received radiotherapy
between January 2004 and October 2013 at our institution. Of
these, 81 (77%) were treated with concurrent chemoradiotherapy at
45 Gy in 30 fractions and were included in this retrospective study
(Table 1). Institutional Review Board approval was obtained for this
study. In this study, LD-SCLC was deﬁned as disease conﬁned to
the ipsi-hemithorax with or without ipsilateral hilar nodes, medi-
astinal nodes, or bilateral supraclavicular nodes metastasis excluding
the bilateral hilar nodes or malignant pleural effusion. The diagnosis
of SCLC was conﬁrmed by histologic or cytologic ﬁndings. Eligi-
bility criteria were as follows: (1) no previous treatment including
surgery or stereotactic ablative body radiotherapy for LD-SCLC;
and (2) an Eastern Cooperative Group Performance Status (PS)
of 0 to 2. All patients underwent the following pre-therapeutic
procedures: a physical examination; chest radiography; ﬁberoptic
bronchoscopy; complete blood cell count and biochemical tests
including tumor markers; electrocardiography; computed tomog-
raphy (CT) imaging of the chest and abdomen; CT or magnetic
resonance imaging of the brain; and bone scintigraphy or positron
emission tomography. All patients were hospitalized for chemo-
radiotherapy and quit smoking during the treatment. A hematologic
status, which included a white blood cell count of > 3500/mm3,
platelet count of > 100,000/mm3, and hemoglobin level of > 10 g/
dL, was required. No patients received prophylactic granulocyte-
colony stimulating factor (G-CSF) before chemoradiotherapy.
When patients developed grade 4 neutropenia, sterilized food was
prepared, and prophylactic antibiotics were used. When patients
developed febrile neutropenia, which was deﬁned as an axillary
temperature of  37.5C with grade 4 neutropenia during che-
moradiotherapy, G-CSF and empiric broad-spectrum antibiotics
were primarily administered. When febrile neutropenia or grade 3
non-hematologic adverse events excluding nausea, vomiting, appe-
tite loss, and elevated creatinine or liver enzymes developed,nical Lung Cancer Month 2016
Table 1 Continued
Patient Characteristic N (%)
Timing of performing twice-daily thoracic
radiotherapy
During the ﬁrst cycle of chemotherapy 70 (86)
During the second cycle of chemotherapy 6 (7)
During the third cycle of chemotherapy 3 (4)
During the fourth cycle of chemotherapy 2 (2)
Duration of chemotherapy, d
Median 87
Range 1-163
Number of patients with performing full dose
of all 4 cycles of chemotherapy
16 (20)
Number of patients using granulocyte-colony
stimulating factor during chemoradiotherapy
38 (47)
Time from the start of any treatment to the
end of chest irradiation, d
Median 29
Range 21-109
Number of patients whose duration of
radiotherapy was prolonged by toxicity
50 (62)
Number of patients whose duration of
radiotherapy included holidays
51 (63)
Number of patients treated with prophylactic
cranial irradiation
53 (65)
aThis patient was complicated with Lambert-Eaton myasthenic syndrome by small-cell lung
cancer.
Masahiro Morimoto et alradiotherapy was generally interrupted. Recovery from febrile neu-
tropenia was deﬁned as an axillary temperature of < 37C with a
neutrophil count of > 500/mm3. LD-SCLC combined with
interstitial pneumonia was principally contraindicated for chemo-
radiotherapy because of an increase in the risk of the acute exac-
erbation of interstitial pneumonia7; however, when the patient and
family understood this risk and still wished to receive standard
treatment, we treated theses as special cases and administrated
chemoradiotherapy. Follow-up was performed every month for the
ﬁrst year, every 2 or 3 months for the second year, every 3 or 4
months for the third to ﬁfth year, and every 6 months after the ﬁfth
year. Close follow-up was performed for early detection of the
recurrence. No patients were lost to follow-up. Adverse events were
evaluated using Common Terminology Criteria for Adverse Events,
Version 4.0. The follow-up time was counted from the day any anti-
cancer treatment was started. Any death was counted as an event in
the overall survival rate. Any death or progression, including distant
metastasis, was counted as an event in the progression-free survival
rate. Any progression in the radiotherapy ﬁeld was counted as an
event in the local control rate.
Radiotherapy
Thoracic radiotherapy was performed BID at a dose of 1.5 Gy
per fraction with an interval of  6 hours between fractions to a
total dose of 45 Gy in 30 fractions given over 3 weeks. The duration
of BID-TRT was deﬁned as days between the start of TRT and the
end of TRT. Radiotherapy was administrated on 5 consecutive days
per week, excluding Saturdays, Sundays, and holidays. For example,the holidays in 2004 were as follows; January 1, 2, 3, 12; February
11; March 20; April 29; May 3, 4, 5; July 19; September 20, 23;
October 11; November 3, 23; and December 23, 29, 30, and 31.
Radiotherapy was performed using a linear accelerator with an
energy of 10 MV photons. After 30 Gy in 20 fractions had been
delivered, the radiotherapy ﬁeld was changed to avoid irradiating the
spinal cord from anterior-posterior opposed large ﬁelds (which
included the elective nodes) to parallel opposed oblique small ﬁelds
(which included only the primary tumor and metastatic lymph
nodes). However, 1 patient whose tumor had aggressively invaded
the contralateral mediastinum was treated using large ﬁelds until 36
Gy in 24 fractions had been delivered and then using small ﬁelds
until 45 Gy in 30 fractions had been delivered. Another patient with
stage I disease received radiotherapy for the primary tumor only
without elective node irradiation until 45 Gy in 30 fractions had
been delivered. A 3-dimensional CT simulation or 2-dimensional
radiograph simulation were used for treatment planning. The
2-dimensional radiograph simulation was used for the ﬁrst 2 years of
this study, but all patients subsequently received 3-dimensional CT
simulation. In the 3-dimensional CT simulation, the clinical target
volume (CTV) 1 was typically a 0.5-cm expansion of the gross
tumor volume including the primary tumor and metastatic lymph
nodes; the planning target volume (PTV) 1 was then a 0.5 to 1 cm
expansion of the CTV1. The CTV2 was subsequently deﬁned as
elective hilar, mediastinal, or supraclavicular lymph nodes plus the
CTV1. The CTV2 included the ipsilateral hilar lymph nodes,
subcarinal nodes, and lower paratracheal nodes. The CTV2 also
included the aortopulmonary window and para-aortic nodes in all
left primary tumors and some right primary tumors. The CTV2
included or excluded the upper paratracheal lymph nodes and
supraclavicular lymph nodes, depending on the decision of the
oncologists regarding tumor spreading. The PTV2 was typically
deﬁned as a 0.5 to 1 cm expansion of the CTV2. Elective nodal
irradiation was performed at doses of 30 Gy for the PTV2, and then
boost irradiation was performed at total doses of 45 Gy for the
PTV1. In the 2-dimensional radiograph simulation, the radio-
therapy ﬁeld included the tumor volume with a  1.5 cm margin
around the mass, and the elective nodal irradiation included the
ipsilateral hilar area, subcarinal area, and lower paratracheal area. All
left-sided tumors included the aortic arch and aortopulmonary
window area. Whether the supraclavicular and upper tracheal areas
were included or excluded depended on the decision of the oncol-
ogists regarding tumor spreading. Slotman et al8 showed the beneﬁt
of prophylactic cranial irradiation in patients with extensive-disease
SCLC after a response to chemotherapy. The deﬁnition of a
response, indicating good responders or stable disease, differs
between institutions. In our institution, prophylactic cranial irra-
diation was administrated to good responders.
Chemotherapy
The concurrent chemotherapy regimen mainly consisted of
cisplatin and etoposide. In patients aged > 75 years, with a low
performance status, low renal function (creatinine clearance < 60
mL/min), a syndrome of the inappropriate secretion of antidiuretic
hormone, or other severe complications, the second choice for
concurrent chemotherapy consisted of carboplatin and etoposide.
The ﬁrst-choice chemotherapy regimen consisted of 80 mg/m2 ofClinical Lung Cancer Month 2016 - 3
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4 - Cliintravenous cisplatin on day 1 and 100 mg/m2 of intravenous eto-
poside on days 1 to 3. The second-choice chemotherapy regimen
consisted of intravenous carboplatin with an area under the curve
(AUC) of 5 on day 1 and 80 mg/m2 etoposide on days 1 to 3. The
dose of cisplatin, etoposide, or carboplatin in subsequent cycles was
reduced by 10 to 20 mg/m2 or AUC of 1 from the planned dose
when grade 4 hematologic toxicity or grade 3 non-hematologic
adverse events occurred. Chemotherapy was interrupted or
changed as a result of prolonged hematologic toxicity, severely
elevated creatinine, pulmonary infection, or chemoradiotherapy-
induced pneumonitis. Chemotherapy was principally performed in
4 cycles every 3 to 4 weeks. The timing of TRT was primarily during
the ﬁrst cycle of concurrent chemotherapy. When the oncologists
determined that the tumor occupied more than one-half of the
ipsilateral lung or when patients were considered too elderly to
perform the ﬁrst cycle of chemoradiotherapy, a second or later cycle
of chemoradiotherapy was administrated. The duration of chemo-
therapy was deﬁned as days between the ﬁrst day of the ﬁrst cycle of
chemotherapy and the ﬁrst day of the last cycle of chemotherapy.
Statistical Analysis
The overall survival, local control, and progression-free survival
rates were estimated using the Kaplan-Meier method, and the sig-
niﬁcant differences were analyzed using the log-rank test. Cox
multivariate and univariate regression analyses were used to assess
overall survival, local control, and progression-free survival. The
forward stepwise method with likelihood ratios was adopted in the
regression analyses. Receiver operating characteristics analysis was
used to decide the optimal cut-off value of the duration of BID-
TRT. A P-value of < .05 was considered signiﬁcant using a
2-sided test. Statistical analyses were performed using SPSS, version
19.0 (IBM, Armonk, NY) and EZR (Saitama Medical Center, Jichi
Medical University),9 a modiﬁed version of R commander designed
to add statistical functions frequently used in biostatistics, including
a graphical user interface for R (The R Foundation for Statistical
Computing).
The Spearman correlation coefﬁcient matrixes were produced in
order to investigate relationships among the time related factorsFigure 1 The Spearman Correlation Coefﬁcients Matrixes of the Time
Radiotherapy (BID-TRT), Time From the Start of Any Treat
Radiotherapy During the Second or Later Cycle of Chemot
nical Lung Cancer Month 2016including the duration of BID-TRT, SER, performing radiotherapy
during the second or later cycle of chemotherapy, and including
holidays during radiotherapy (Figure 1). The combination of the
duration of BID-TRT and SER had relatively high correlation
coefﬁcients (0.697). The other combination of SER and performing
radiotherapy during the second or later cycle of chemotherapy had
also relatively high correlation coefﬁcients (0.596). Thus, these
combinations were excluded from Cox multivariate regression
analyses in order to control confounding factors that may negatively
affect the generalizability of the Cox multivariate regression model.
Multivariate Cox regression analyses were performed using sig-
niﬁcant or marginally signiﬁcant factors with P-values that were less
than .06 in Cox univariate regression analyses. Furthermore, the
duration of BID-TRT, which was the focus of this study, was
included in Cox multivariate regression analyses on overall survival
and progression-free survival even though it was not signiﬁcant in
the Cox univariate regression analyses (Tables 2 and 3). However,
the duration of BID-TRT was excluded from Cox multivariate
regression analyses on local control (Table 4) because SER was a
signiﬁcant factor in the Cox univariate regression analysis of local
control and had relatively high Spearman correlation coefﬁcients
with the duration of BID-TRT (Figure 1). Also, performing
radiotherapy during the second or later cycle of chemotherapy was
excluded from Cox multivariate regression analyses on local control
(Table 4) in spite of its marginal signiﬁcance in the Cox univariate
regression analysis because it had relatively high Spearman correla-
tion coefﬁcients with SER (Figure 1).
Results
The median follow-up period was 21 months (range, 2-117
months). All 81 patients completed radiotherapy with a total dose of
45 Gy in 30 fractions. The median duration of BID-TRT was 25
days (range, 21-38 days), and its distribution is shown in Figure 2.
Chemoradiotherapy-induced adverse events are listed in Table 5. The
2-, 3-, and 5-year overall survival rates in all 81 patients were 55.8%
(95% conﬁdence interval [CI], 44.0%-67.6%), 44.9% (95% CI,
32.6%-57.2%), and 26.2% (95% CI, 14.3%-38.0%), respectively,
and the median survival time was 30 months (95% CI, 15.5-44.5-Related Factors That Were the Duration of Twice-Daily Thoracic
ment to the End of Chest Irradiation (SER), Performing
herapy, and Including Holidays During Radiotherapy
Table 2 Analyses in the Multivariate and Univariate Cox Proportional Hazard Models of Overall Survival
Factors
Multivariate Analyses Univariate Analyses
P Value HR 95% CI P Value HR 95% CI
Sum of the diameters of the primary tumor and
metastatic lymph nodes, cm
.001 1.15 1.06-1.25 .006 1.12 1.03-1.22
Male (vs. female) .022 2.38 1.13-5.02 .04 2.16 1.04-4.48
60 years (vs. <60 years) .028 2.38 1.10-5.17 .053
Duration of twice-daily thoracic radiotherapy, d .029 1.08 1.01-1.15 .19
Patients with grade 2 chemoradiotherapy-induced
pneumonitis (vs. with grade 1 or no pneumonitis)
.14 .009 2.35 1.24-4.45
Not performing prophylactic cranial irradiation (vs.
performing)
.356 .018 2.03 1.13-3.64
Irradiated volume of the body, cm3 Not included .088
Performance status 1 (vs. performance status 0)a Not included .134
Time from the start of any treatment to the end of
chest irradiation, d
Not included .162
Performing radiotherapy during the second or later
cycle of chemotherapy (vs. during the ﬁrst cycle of
chemotherapy)
Not included .179
Pretreatment hemoglobin level, g/dL Not included .267
Not performing full dose of all 4 cycles of
chemotherapy (vs. performing full dose of all 4 cycles
of chemotherapy)
Not included .324
Prolonged duration of radiotherapy due to toxicity
(vs. not prolonged duration of radiotherapy due to
toxicity)
Not included .353
Patients with diabetes mellitus (vs. without diabetes
mellitus)
Not included .4
Performing 3 cycles of chemotherapy (vs. 4 cycles
of chemotherapy)
Not included .403
Not performing positron emission tomography for
staging (vs. performing)
Not included .476
Performing 2-dimensional radiograph simulation
(vs. 3-dimensional computed tomography simulation)
Not included .484
Including holidays during radiotherapy (vs. not
including holidays)
Not included .54
Pretreatment pro-gastrin-releasing peptide level, pg/mL Not included .57
Stage III (vs. Stage I or II) Not included .578
Use of granulocyte-colony stimulating factor during
chemoradiotherapy (vs. no use)
Not included .617
Patients with chemoradiotherapy-induced febrile
neutropenia (vs. without febrile neutropenia)
Not included .635
Use of carboplatin and etoposide for initial
chemotherapy (vs. cisplatin and etoposide)
Not included .771
Duration of chemotherapy, d Not included .937
Bold values statistically signiﬁes P < .05.
Abbreviations: CI ¼ conﬁdence interval; HR ¼ hazard ratio.
aThis division was used because there were only 3 patients with performance status 2 to 4.
Masahiro Morimoto et almonths) (Figure 3). The Cox multivariate regression analysis iden-
tiﬁed as signiﬁcant predictors of survival the sum of the diameters of
the primary tumor and metastatic lymph nodes, male gender, age 
60 years, and the duration of BID-TRT (Table 2). The optimal cut-
off value of the duration of BID-TRT was 29 days in the receiver
operating character analysis (AUC, 0.53), and the median survival
time was signiﬁcantly longer in the 64 patients with a duration of
BID-TRT 29 days than in the 17 patients with a duration of BID-
TRT > 29 days (36 months [95% CI, 24.4-47.6 months] vs. 12
months [95% CI, 9.0-15.0 months]; P ¼ .004) (Figure 4).The reasons for prolonging the duration of BID-TRT were
toxicity-interrupting radiotherapy and holidays. Chemo-
radiotherapy-induced  grade 3 esophagitis was observed in 1
patient (1%) (Table 5). Thus, that was not a main factor prolonging
the duration of BID-TRT. The most frequent toxicity that pro-
longed the duration of BID-TRT was febrile neutropenia, which
accounted for 70% of cases (35 of 50) of toxicity-interrupting
radiotherapy. Radiotherapy was generally interrupted until recov-
ery from febrile neutropenia; however, the timing to re-start
radiotherapy depended on the decision of each oncologist. TheClinical Lung Cancer Month 2016 - 5
Table 3 Analyses in the Multivariate and Univariate Cox Proportional Hazard Models of Progression-Free Survival
Factors
Multivariate Analyses Univariate Analyses
P Value HR 95% CI P Value HR 95% CI
Not performing prophylactic cranial irradiation (vs. performing) .021 1.91 1.1-3.32 .009 2.06 1.2-3.55
Irradiated volume of the body, cm3 .031 1 1-1.001 .013 1 1-1.001
Male (vs. female) .056 .019 2.18 1.14-4.17
Patients with grade 2 chemoradiotherapy-induced pneumonitis
(vs. with grade 1 or no pneumonitis)
.136 .016 2.11 1.15-3.86
Duration of twice-daily thoracic radiotherapy, d .145 .209
Sum of the diameters of the primary tumor and metastatic lymph
nodes, cm
.272 .014 1.09 1.02-1.17
Time from the start of any treatment to the end of chest
irradiation, d
Not included .086
60 years (vs. <60 years) Not included .101
Performing radiotherapy during the second or later cycle of
chemotherapy (vs. during the ﬁrst cycle of chemotherapy)
Not included .127
Performing 2-dimensional radiograph simulation (vs. 3-dimensional
computed tomography simulation)
Not included .137
Pretreatment hemoglobin level, g/dL Not included .164
Not performing full dose of all 4 cycles of chemotherapy (vs.
performing full dose of all 4 cycles of chemotherapy)
Not included .18
Duration of chemotherapy, d Not included .215
Prolonged duration of radiotherapy due to toxicity (vs. not prolonged
duration of radiotherapy due to toxicity)
Not included .249
Stage III (vs. Stage I or II) Not included .3
Performing 3 cycles of chemotherapy (vs. 4 cycles of
chemotherapy)
Not included .48
Performance status 1 (vs. performance status 0)a Not included .492
Not performing positron emission tomography for staging (vs.
performing)
Not included .495
Use of granulocyte-colony stimulating factor during
chemoradiotherapy (vs. no use)
Not included .609
Use of carboplatin and etoposide for initial chemotherapy
(vs. cisplatin and etoposide)
Not included .674
Pretreatment pro-gastrin-releasing peptide level, pg/mL Not included .705
Patients with chemoradiotherapy-induced febrile neutropenia
(vs. without febrile neutropenia)
Not included .774
Patients with diabetes mellitus (vs. without diabetes mellitus) Not included .957
Including holidays during radiotherapy (vs. not including holidays) Not included .962
Bold values statistically signiﬁes P < .05.
Abbreviations: CI ¼ conﬁdence interval; HR ¼ hazard ratio.
aThis division was used because there were only 3 patients with performance status 2 to 4.
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14 patients with febrile neutropenia if radiotherapy had been
immediately re-started after recovery from febrile neutropenia.
The mean ages in patients with and without febrile neutropenia
were 67 years and 64 years, respectively (P ¼ .079; not signiﬁcant).
The percentages of the patients with a PS 0 among the patients with
and without febrile neutropenia were 51% (20 of 39 patients) and
40% (17 of 42 patients), respectively (P ¼ .329; not signiﬁcant).
The median survival time in the 30 patients whose duration of
BID-TRT did not include holidays, and that in the 51 patients
whose duration of BID-TRT included holidays was 37 months
(95% CI, 23.9-50.1 months) and 29 months (95% CI, 19.0-39.0
months), respectively (P ¼ .535; not signiﬁcant) (see Supplemental
Figure 1 in the online version). The median survival time in the 31
patients whose duration of BID-TRT was not prolonged owing tonical Lung Cancer Month 2016toxicity and that in the 50 patients whose duration of BID-TRT
was prolonged owing to toxicity was 30 months (95% CI,
14.0-46.0 months) and 29 months (95% CI, 13.1-44.9 months),
respectively (P ¼ .348; not signiﬁcant) (see Supplemental Figure 2
in the online version).
The 2-, 3-, and 5-year local control rates in all 81 patients were
58.1% (95% CI, 44.7%-71.5%), 52.2% (95% CI, 37.9%-66.5%),
and 48.7% (95% CI, 33.9%-63.6%), respectively, and the median
local control time was 41 months (95% CI was not calculated)
(Figure 3). The Cox multivariate regression analysis identiﬁed as sig-
niﬁcant predictors of local control the sum of the diameters of the
primary tumor and metastatic lymph nodes, age  60 years, and SER
(Table 4).
The 2-, 3-, and 5-year progression-free survival rates in all 81
patients were 28.0% (95% CI, 17.5%-38.5%), 24.5% (95% CI,
Table 4 Analyses in the Multivariate and Univariate Cox Proportional Hazard Models of Local Control
Factors
Multivariate Analyses Univariate Analyses
P Value HR 95% CI P Value HR 95% CI
Sum of the diameters of the primary tumor and metastatic lymph
nodes, cm
.003 1.18 1.06-1.31 .011 1.13 1.03-1.25
60 years (vs. <60 years) .022 4.18 1.23-14.24 .052
Time from the start of any treatment to the end of chest
irradiation, d
.03 1.02 1-1.04 .031 1.02 1-1.04
Not performing prophylactic cranial irradiation (vs. performing) .097 .012 2.64 1.23-5.65
Performing radiotherapy during the second or later cycle of
chemotherapy (vs. during the ﬁrst cycle of chemotherapy)
Not included .058
Stage III (vs. Stage I or II) Not included .084
Male (vs. female) Not included .112
Irradiated volume of the body, cm3 Not included .179
Patients with diabetes mellitus (vs. without diabetes mellitus) Not included .189
Performing 3 cycles of chemotherapy (vs. 4 cycles of
chemotherapy)
Not included .207
Duration of chemotherapy, d Not included .237
Pretreatment pro-gastrin-releasing peptide level, pg/mL Not included .24
Use of carboplatin and etoposide for initial chemotherapy
(vs. cisplatin and etoposide)
Not included .25
Duration of twice-daily thoracic radiotherapy, d Not included .308
Pretreatment hemoglobin level, g/dL Not included .312
Prolonged duration of radiotherapy due to toxicity (vs. not
prolonged duration of radiotherapy due to toxicity)
Not included .394
Not performing full dose of all 4 cycles of chemotherapy
(vs. performing full dose of all 4 cycles of chemotherapy)
Not included .604
Including holidays during radiotherapy (vs. not including holidays) Not included .641
Performance status 1 (vs. performance status 0)a Not included .713
Performing 2-dimensional radiograph simulation (vs. 3-dimensional
computed tomography simulation)
Not included .73
Patients with chemoradiotherapy-induced febrile neutropenia
(vs. without febrile neutropenia)
Not included .757
Use of granulocyte-colony stimulating factor during
chemoradiotherapy (vs. no use)
Not included .818
Patients with grade 2 chemoradiotherapy-induced pneumonitis
(vs. with grade 1 or no pneumonitis)
Not included .872
Not performing positron emission tomography for staging
(vs. performing)
Not included .942
Bold values statistically signiﬁes P < .05.
Abbreviations: CI ¼ conﬁdence interval; HR ¼ hazard ratio.
aThis division was used because there were only 3 patients with performance status 2 to 4.
Masahiro Morimoto et al14.2%-34.7%), and 19.0% (95% CI, 8.7%-29.4%), respectively,
and the median progression-free survival time was 11 months (95%
CI, 8.3%-13.7%) (Figure 3). The Cox multivariate regression
analysis identiﬁed as signiﬁcant predictors of progression-free sur-
vival performing prophylactic cranial irradiation and the irradiated
volume of the body (Table 3).
Discussion
Signiﬁcance of the Duration of BID-TRT and SER
Multivariate analyses identiﬁed the following signiﬁcant pre-
dictors of survival in LD-SCLC patients; the sum of the diameters
of the primary tumor and metastatic lymph nodes (a tumor factor);
male gender and age  60 years (patient factors); and the duration
of BID-TRT (a treatment factor). The inﬂuence of the duration of
radiotherapy on the outcomes of LD-SCLC, which is generallyconsidered to be a rapidly proliferating cancer, has been contro-
versial. Actually, Bogart et al10 reported that interruptions in once-
daily thoracic radiotherapy did not correlate with the outcomes of
LD-SCLC patients at a total dose of 50 Gy delivered in 25 fractions
over 5 weeks (once-daily conventional schedules involving 2 Gy/
fraction). They showed that the median survival times were 21.7,
18.1, and 23.8 months in the 0 to 3 days interrupted group, the 4
to 10 days interrupted group, and the > 10 days interrupted group,
respectively. These differences were not signiﬁcant. However, the
opposite ﬁndings were obtained using an accelerated radiotherapy
regimen. Videtic et al11 demonstrated that treatment interruptions
to palliate the toxicity of concurrent chemoradiotherapy for LD-
SCLC decreased survival and disease control at mainly 40 Gy
delivered in 15 fractions over 3 weeks (once daily accelerated
schedules involving 2.67 Gy/fraction). They reported that theClinical Lung Cancer Month 2016 - 7
Figure 2 Distribution of the Duration of Twice-Daily Thoracic Radiotherapy
Table 5 Adverse Events Caused by Chemoradiotherapy
Adverse Event N (%)
Febrile neutropenia
Grade 3 39 (48)
Grade 4 0
Grade 5 0
Pneumonitis
Grade 1 42 (52)
Grade 2 11 (14)
Grade 3 3 (4)
Grade 4 0
Grade 5 3 (4)a
Esophagitis
Grade 1 41 (51)
Grade 2 8 (10)
Grade 3 1 (1)
Grade 4 0
Grade 5 0
Thrombocytopenia
Grade 1 40 (49)
Grade 2 12 (15)
Grade 3 9 (11)
Grade 4 1 (1)
Anemia
Grade 1 58 (72)
Grade 2 14 (17)
Grade 3 3 (4)
Grade 4 0
Grade 5 0
aIncluding 2 patients who died of the chemoradiotherapy-induced acute exacerbation of
interstitial pneumonia.
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8 - Clinical Lung Cancer Month 2016median survival time was 15.6 months in the uninterrupted group,
which was signiﬁcantly longer than 13.8 months in the interrupted
group (P ¼ .014). Our results using 45 Gy delivered in 30 fractions
over 3 weeks (BID accelerated hyperfractionated schedules
involving 1.5 Gy/fraction) generally corresponded with the ﬁndings
of Videtic et al. Withers et al12 found that accelerated tumor clo-
nogen repopulation occurred 4 weeks after the commencement of
radiotherapy in head and neck cancer. The mean tumor doubling
time of 43 days in small-cell lung cancer13 was shorter than that in
oropharyngeal cancer of 96 days.14 We speculated that cancers such
as small-cell lung cancer, which is more rapidly proliferating than
head and neck cancer, had a shorter duration of accelerated tumor
clonogen repopulation. Thus, the duration of radiotherapy may
biologically impact on SCLC cell survival. Although a meta-analysis
by De Ruysscher et al6 showed that SER was the most important
predictor of survival in LD-SCLC patients, this meta-analysis did
not reveal whether the actual duration of BID-TRT was a signiﬁ-
cant predictor of survival. Our study is unique because all patients
received BID-TRT of 45 Gy in 30 fractions, and the actual
duration of radiotherapy are analyzed. In addition, although De
Ruysscher et al6 reported that SER did not correlate with
local control, our study showed that SER did correlate with local
control.
Febrile Neutropenia Prolonged the Duration of BID-TRT
In the present study, febrile neutropenia was the main reason
for the prolongation of the duration of BID-TRT. In addition, the
duration of BID-TRT would have decreased in some patients with
febrile neutropenia if radiotherapy had been re-started immedi-
ately after recovery from febrile neutropenia. Careful monitoring
of the white blood cell count and body temperature is necessary to
safely re-start radiotherapy under these circumstances. Washing
the hands and throat, eating sterilized food, using an isolator,
using a clean room, and taking prophylactic and empiric antibi-
otics may be essential for decreasing the frequency and recovery
Figure 4 Overall Survival Rate in the 64 Patients With Limited-
Disease Small-Cell Lung Cancer Treated Within 29
Days of the Duration of Twice-Daily Thoracic
Radiotherapy (BID-TRT) (Solid Line), and That in the
Other 17 Patients Treated Beyond 29 Days of the
Duration of BID-TRT (Dotted Line). The Optimal Cut-
Off Value of 29 Days Was Calculated From Receiver
Operating Characteristics Analysis
Figure 3 Overall Survival Rate (OS) (Solid Line), Local Control
Rate (LC) (Dotted Line), and Progression-Free
Survival Rate (PFS) (Dashed Line) in All 81 Patients
With Limited-Disease Small-Cell Lung Cancer
Treated With Concurrent Chemoradiotherapy
Masahiro Morimoto et altime of febrile neutropenia. Although Bunn et al15 previously
recommended that prophylactic G-CSF should not be indicated
for LD-SCLC, therapeutic G-CSF was essential for recovery from
febrile neutropenia with careful monitoring for thrombocytopenia.
As collateral evidence, Clark et al16 reported that G-CSF shortened
the hospitalization time and neutrophil recovery time in patients
with febrile neutropenia. In the present study, therapeutic G-CSF
was not a signiﬁcant factor affecting survival. In the future, the
palliation of myelosuppression may be possible by reducing the
radiation dose to the vertebral column using intensity-modulated
radiation therapy. In the present study, the severe esophagitis
was so rare that no correlation was observed with prolongation of
the duration of BID-TRT. The frequency of severe esophagitis in
our study or others from Eastern Asia17,18 was 1% to 4% lower
than that reported in Western countries (19%-33%).2,5 The
reason for this currently remains unclear; however, we speculated
that the difference may be related to the lower rate of gastro-
esophageal reﬂux disease in Asian countries than in Western
countries.19
Conclusions
The interpretation of the effects of the duration of radiotherapy
on the outcomes of LD-SCLC was valid because the total dose,
number of fractions of radiation, and concurrent chemotherapy of
platinum and etoposide were not varied. The duration of BID-TRT
at a total dose of 45 Gy in 30 fractions and SER were one of the
signiﬁcant predictors of survival and local control in patients withLD-SCLC, respectively. Febrile neutropenia was the main factor
responsible for prolonging the duration of BID-TRT. Re-starting
radiotherapy immediately after recovery from febrile neutropenia
needs to be considered in order to improve the prognosis of patients
with LD-SCLC.
Clinical Practice Points
 The topic of radiotherapy duration on the outcomes in limited-
disease small-cell lung cancer (LD-SCLC) remains unresolved
and requires further research.
 One study revealed that interruptions in once-daily thoracic
radiotherapy did not correlate with the outcomes of LD-SCLC
patients at a total dose of 50 Gy in 25 fractions over 5 weeks.
 The present study contains the opposite new ﬁndings about the
signiﬁcance of the duration of twice-daily thoracic radiotherapy
in relation to the survival of patients with LD-SCLC receiving
standard concurrent chemoradiotherapy (platinum and etoposide
at 45 Gy in 30 fractions over 3 weeks). Our interpretation about
radiotherapy duration were valid because all patients completed
45 Gy/30 fractions. Additionally, we detected that febrile neu-
tropenia, not esophagitis, was a main factor responsible for the
prolongation of the radiotherapy duration.
 For minimizing the negative inﬂuence of febrile neutropenia on
the radiotherapy duration, radiotherapy should be re-started
immediately after recovery from febrile neutropenia. Any sup-
port care should be done to decrease the frequency and recovery
time of febrile neutropenia.
 Although one study previously recommended that prophylactic
granulocyte-colony stimulating factor (G-CSF) should not beClinical Lung Cancer Month 2016 - 9
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10 -indicated for LD-SCLC, therapeutic G-CSF was essential for
recovery from febrile neutropenia with careful monitoring for
thrombocytopenia. In the present study, therapeutic G-CSF was
not a signiﬁcant factor affecting survival.
 The palliation of myelosuppression may be possible by reducing
the radiation dose to the vertebral column using intensity
modulated radiation therapy. Our new ﬁndings will contribute
to improve the prognosis in LD-SCLC.Acknowledgments
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Supplemental Figure 1 Overall Survival Rate in the 30 Patients
Whose Duration of Twice-Daily
Thoracic Radiotherapy Did Not Include
Holidays (Solid Line) and That in the 51
Patients Whose Duration of Twice-
Daily Thoracic Radiotherapy Included
Holidays (Dotted Line)
Supplemental Figure 2 Overall Survival Rate in the 31 Patients
Whose Duration of Twice-Daily
Thoracic Radiotherapy Were Not
Prolonged by Toxicity (Solid Line) and
That in the 50 Patients Whose Duration
of Twice-Daily Thoracic Radiotherapy
Were Prolonged by Toxicity (Dotted
Line)
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